Ivie v. AstraZeneca Pharmaceuticals, LP

CourtDistrict Court, D. Oregon
DecidedMarch 28, 2021
Docket3:19-cv-01657
StatusUnknown

This text of Ivie v. AstraZeneca Pharmaceuticals, LP (Ivie v. AstraZeneca Pharmaceuticals, LP) is published on Counsel Stack Legal Research, covering District Court, D. Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ivie v. AstraZeneca Pharmaceuticals, LP, (D. Or. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF OREGON

SUZANNE IVIE, No. 3:19-cv-01657-HZ

Plaintiff, OPINION & ORDER

v.

ASTRAZENECA PHARMACEUTICALS, LP,

Defendant.

Anita Mazumdar Chambers Robert Scott Oswald The Employment Law Group 888 17th Street, NW Washington, DC 20006

David C. Rocker Catalyst Law, LLC 810 NW Marshall St, Ste 300 Portland, OR 97209

Collin C. McKean McKean Smith LLC 1140 SW 11th Ave Ste 400 Portland, OR 97205

Attorneys for Plaintiff Courtney Sanders Ryan P. McCarthy Morgan, Lewis & Bockius LLP 1000 Louisiana St. Suite 4000 Houston, TX 77002

John C. Dodds Philadelphia Litigation 1701 Market Street, Ste 14th Floor Philadelphia, PA 19103-2921

Anne M. Talcott Schwabe, Williamson & Wyatt 1211 SW 5th Ave, Ste. 1900 Portland, OR 97204

Attorneys for Defendant

HERNÁNDEZ, District Judge: Plaintiff Suzanne Ivie brings this employment discrimination and retaliation action against Defendant AstraZeneca Pharmaceuticals, LP. Defendant moves for summary judgment on each of Plaintiff's claims. The Court grants in part and denies in part Defendant's motion for summary judgment. BACKGROUND AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medications. Answer ¶ 9. Plaintiff worked at AstraZeneca for 19 years. Id. ¶ 11. In her last role she was an Executive District Sales Manager (DSM) in Defendant’s respiratory products division. First Talcott Decl. Ex. B at 13, ECF 42-1. The respiratory products division sells several products including Symbicort, Dalisrep, and Bevespi. Pl.’s Opp’n Mem. Ex. NN (DiNunzio Dep.) 40:18-22, ECF 43-40. /// /// I. Plaintiff’s Off-Label Marketing and Discrimination Complaints In October 2017, Stephanie DiNunzio became Plaintiff’s direct supervisor as the commercial business director. First Talcott Decl. Ex. C (DiNunzio Dep.) 51:9-15, 19:19-20:2, ECF 42-1. DiNunzio over saw the respiratory and health therapeutic sales area for the Seattle

region. Id. The respiratory sales team uses a sales strategy called “Selling with Insights” to approach customer physicians. Pl.’s Opp’n Mem. Ex. RR (Craig Dep.) 20:14-21:6, ECF 43-44. This strategy involves discussing various drugs’ indications with physicians in order to start a conversation about the AstraZeneca pharmaceutical product. Id. The “insights” are not about the pharmaceutical product itself, but about the problem or patient type the medication might be used to treat. Pl.’s Opp’n Mem. Ex. NN (DiNunzio Dep.) 119:2-5. “Insights” can be developed by members of the sales team, but they must be true and meet AstraZeneca’s compliance standards. Id. at 119:6-11. In August 2018 DiNunzio contacted Plaintiff regarding some possible “new insights” for

Symbicort. Pl.’s Opp’n Mem. Ex. C at 3, ECF 43-3. At the time, Plaintiff was a Compliance Ambassador for the company. Answer ¶ 40. DiNunzio asked and then allegedly pressured Plaintiff to approve the use of the proposed Symbicort insights. Pl.’s Opp’n Mem. Ex. D at 1, ECF 43-4. Plaintiff became concerned that the Symbicort insights proposed by DiNunzio raised compliance issues. Id. She contacted an AstraZeneca’s compliance officer about her concerns. Pl.’s Opp’n Mem. Ex. C at 1–3. After a phone conversation with Plaintiff, the compliance officer sent Plaintiff and DiNunzio an email describing AstraZeneca’s “Selling with Insights” rules and recommending DiNunzio follow-up with further team training on the insights program. Id. at 2. DiNunzio allegedly responded to the email by telling Plaintiff that she should not have gotten anyone else involved and that she needed to reevaluate Plaintiff’s role as a Regional Compliance Ambassador. Pl.’s Opp’n Mem. Ex. D. At two other points in August 2018 DiNunzio allegedly responded to Plaintiff’s compliance concerns with threats of cutting back Plaintiff’s national leadership exposure and “reevaluating her role as a compliance champion.” Id.

In December 2018 Plaintiff became concerned about another set of insights proposed for the drug Daliresp. Plaintiff testified that in a meeting discussing insights for Daliresp, DiNunzio said that 50% of patients with mild to moderate conditions die when they have their first exacerbation. Pl.’s Opp’n Mem. Ex. SS (Ivie Dep.) 172:10-21, ECF 43-45. Plaintiff felt that this insight was “pushing the limits” and “illegal.” Id. at 172:22-25. During a follow-up investigation, another employee at the same meeting recalled DiNunzio bringing up the need to increase the Daliresp patient population by promoting Daliresp for primary prevention. Pl.’s Opp’n Mem. Ex. E at 2, ECF 43-5. On December 19, 2018 Plaintiff filed a formal complaint against DiNunzio. Pl.’s Opp’n Mem. Ex. D. Her complaint raised concerns of off-label marketing based on the improper

proposed insights described above and retaliation after voicing her concerns. Id. Plaintiff also reported age discrimination. Id. Her complaint references multiple incidents in 2018 where DiNunzio allegedly made comments referencing age such as “you are all about the old way, and if you can’t get on this new bus you have to leave,” “the old bus is too expensive to the organization,” “the old people need to get off the bus,” and allegedly called Plaintiff an “old bus person.” Id. at 1. On February 5, 2019 Plaintiff filed a second formal complaint related to the unethical use of insights for Daliresp, Symbicort, and Bevespi. Pl.’s Opp’n Mem. Ex. G at 2, ECF 43-7. The concerns stemmed from insights shared on a call and later forwarded in an email that suggested patients with Chronic Obstructive Pulmonary Disease and anxiety and/or depression were at a higher risk for exacerbations and severe illness. Pl.’s Opp’n Mem. Ex. F at 1, ECF 43-6. In response to the first formal complaint, Karen Belknap, a senior employment practices partner, was as assigned to investigate Plaintiff’s complaints of discrimination. Pl.’s Opp’n Mem.

Ex. OO (Belknap Dep.) 16:16, ECF 43-41. Mike Pomponi, Senior Manager of Commercial Compliance Monitoring, was assigned to investigate Plaintiff’s compliance complaints related to off-label marketing. Pl.’s Opp’n Mem. Ex. TT (Pomponi Dep.) 47:13-48:5, ECF 43-46. II. Plaintiff’s Job Performance Before 2018 Plaintiff was considered a top performer. Pl.’s Opp’n Mem. Ex. NN (DiNunzio Dep.) 43:21-44:11, 45:24-46:25. In June 2018 DiNunzio met with Plaintiff to raise concerns about Plaintiff’s coaching of sale specialists on her team. First Talcott Decl. Ex. E., ECF 42-1 at 37. These concerns were based on a policy AstraZeneca had at the time that stated that “Coaching without Customer Engagement” and “Business Development” could count towards a district sales manager’s total coaching days but should not comprise more than 20% of

total coaching days.1 First Talcott Decl. Ex. L at 2, ECF 42-2. According to the policy, “Coaching without Customer Engagement” refers to coaching done by district sales managers when not in the field such as distance and virtual coaching. Id.; First Talcott Decl. Ex. K at 1, ECF 42-2. “Coaching with Customer Engagement” refers to coaching conducted in the field with pharmaceutical sales specialists making calls on customer physicians. Id.; First Talcott Decl. Ex. M at 1, ECF 42-2. This policy was discussed in and attached to emails Plaintiff was copied on

1 In its briefing, Defendant repeatedly refers to this policy as the “80/20 rule.” The written policy in the record is titled “Capturing Time Allocation in Veeva Frequently Asked Questions” (Capturing Time FAQ). First Talcott Decl. Ex. L. As a matter of convenience, the Court refers to the policy as the 80/20 rule and 80/20 policy throughout this opinion and order. before the June 2018 meeting. First Talcott Decl. Ex. J at 1, ECF 42-2; First Talcott Decl. Ex. K at 1, ECF 42-2.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Texas Department of Community Affairs v. Burdine
450 U.S. 248 (Supreme Court, 1981)
Hazen Paper Co. v. Biggins
507 U.S. 604 (Supreme Court, 1993)
St. Mary's Honor Center v. Hicks
509 U.S. 502 (Supreme Court, 1993)
Hawn v. Executive Jet Management, Inc.
615 F.3d 1151 (Ninth Circuit, 2010)
Dawson v. Entek International
630 F.3d 928 (Ninth Circuit, 2011)
Earl v. Nielsen Media Research, Inc.
658 F.3d 1108 (Ninth Circuit, 2011)
Devon Shelley v. Pete Geren
666 F.3d 599 (Ninth Circuit, 2012)
Moran v. Selig
447 F.3d 748 (Ninth Circuit, 2006)
William Schechner v. Kpix-Tv
686 F.3d 1018 (Ninth Circuit, 2012)
Reeves v. Sanderson Plumbing Products, Inc.
530 U.S. 133 (Supreme Court, 2000)
Bias v. Moynihan
508 F.3d 1212 (Ninth Circuit, 2007)
Diaz v. Eagle Produce Ltd. Partnership
521 F.3d 1201 (Ninth Circuit, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
Ivie v. AstraZeneca Pharmaceuticals, LP, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ivie-v-astrazeneca-pharmaceuticals-lp-ord-2021.